Surgical interventions remain the dominant segment. Procedures such as open flap debridement and bone regeneration are considered the gold standard for managing moderate-to-severe cases because they allow clinicians direct access for mechanical debridement, detoxification, and the placement of bone grafts.
AI is driving a shift toward proactive intervention. A notable development is Dentsply Sirona’s 2025 rollout of an AI-integrated imaging platform designed to improve the diagnosis of early-stage peri-implantitis, allowing for minimally invasive treatments before the condition progresses.
The market is primarily fueled by the rapid increase in dental implant surgeries due to ageing populations, cosmetic dentistry trends, and trauma restorations. Additionally, rising patient awareness regarding oral health and a preference for aesthetically appealing, long-lasting implants are pushing clinicians to adopt advanced management systems.
Regenerative dentistry is a major growth area. Companies like the Straumann Group and Zimmer Biomet are developing next-generation bone grafts and bioactive materials to repair bone defects caused by peri-implantitis, which improves implant stability and reduces the risk of recurrence.
Laser debridement is expanding rapidly as a minimally invasive alternative to traditional surgery. These technologies, such as the FDA-cleared devices from BioHorizons, allow for the decontamination of implant surfaces without mechanical trauma, resulting in less postoperative discomfort and faster patient recovery.
North America currently leads the market due to its advanced clinical infrastructure and high implant adoption rates. However, the Asia-Pacific region (specifically China, India, and South Korea) is the fastest-growing market, driven by rising disposable incomes and expanding dental tourism.
Implantoplasty is a niche surgical segment involving the smoothing and polishing of infected implant surfaces. By reducing surface roughness, this technique decreases bacterial biofilm accumulation, significantly improving long-term maintenance outcomes for complex cases.
The primary obstacles include high treatment complexity, significant cost sensitivity, and a lack of standardized reimbursement policies. These factors make advanced regenerative and laser-based therapies less accessible to patients in emerging economies.
The market is led by major dental technology and pharmaceutical firms, including the Straumann Group, Dentsply Sirona, Zimmer Biomet, BioHorizons, Nobel Biocare Services AG, Henry Schein, Osstem Implant, Megagen Implant, Geistlich Pharma AG, and Young Innovations Inc.
